BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET.
A live webcast of the presentation will be accessible under “Events” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
Media Contact
Kristin Politi
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
973-495-5221
Investor Relations Contact
Heather DiVecchia
Elicio Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
857-209-0153
| Last Trade: | US$4.89 |
| Daily Change: | 0.03 0.62 |
| Daily Volume: | 8,055 |
| Market Cap: | US$52.770M |
January 30, 2025 December 12, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
